Literature DB >> 6184573

Heterogeneity of systemic hemodynamic response to a new calcium entry blocker, nitrendipine.

F M Fouad, M Aboul-Khair, R C Tarazi.   

Abstract

The hemodynamic effects of nitrendipine, a new calcium entry blocker, have been evaluated both experimentally and in hypertensive patients. The acute hemodynamic effects (left atrial injection of radioactive microspheres) were studied in normotensive and hypertensive (2K-1 Clip, Goldblatt) Sprague-Dawley rats; two dose levels were used intravenously: 0.3 and 3.0 mg/kg body weight. Arterial blood pressure was reduced in both groups in a dose dependent manner. Cardiac output increased with the higher dose but was reduced with the smaller dose. In humans, nitrendipine was given in a dose of 20 mg b.i.d. for 2 weeks to nine hypertensive patients. The reduction in blood pressure was due to a decrease in systemic resistance (52 +/- 9.7 (SD) to 39 +/- 5.4 u X M2, p less than 0.05); both cardiac output and heart rate response varied among patients (+ 2.1 to -0.97 L/min and + 19 to 4 bpm, respectively). Vasodilators have been previously classified according to predominance of their effects on venous or arterial system. Results of this study suggested that the same vasodilator could fall in one or the other subdivision depending on the dose used and possibly on individual responses.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6184573

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

1.  Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients.

Authors:  J R M'Buyamba-Kabangu; B Lepira; R Fagard; P Lijnen; M Ditu; K A Tshiani; A Amery
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Antihypertensive efficacy and effects of nitrendipine on cardiac and renal hemodynamics in mild to moderate hypertensive patients: randomized controlled trial versus hydrochlorothiazide.

Authors:  R Scaglione; A Indovina; G Parrinello; R Lipari; L G Mulè; A Ganguzza; G Capuana; C G Stampino; G Licata
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.